---
annotation-target: Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-29T12:03:58.991Z","text":"吲哚胺2，3-双加氧酶（IDO）是一种胞内酶，催化L-色氨酸转化为N-甲酰基尼氨酸，是基尼氨酸途径中的第一步和速率控制步骤。 IDO是一种限速酶，催化色氨酸降解为酪氨酸，被认为对需要色氨酸增殖的T细胞具有耐受作用。IDO在功能性静止调节性T细胞的激活和调节中也起着重要作用。 IDO是一种含血红素的酶，催化吲哚环2,3双键的氧化裂解。IDO通过色氨酸饥饿抑制T细胞的活化，而T细胞的存活和增殖则受O2自由基和kynurenine衍生物的调节。IDO在自身免疫、感染和恶性肿瘤中起着至关重要的作用。 吲哚胺-2,3-双加氧酶（IDO）是一种重要的免疫调节酶，参与色氨酸的代谢，是Kynurenin途径的一部分。色氨酸在肿瘤组织中被肿瘤细胞或抗原提呈细胞表达的限速酶IDO分解。","updated":"2022-08-29T12:03:58.991Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":653,"end":683},{"type":"TextQuoteSelector","exact":"r Indolamine-2,3-dioxygenase 1","prefix":"22AbstractPurpose  Strategies fo","suffix":" (IDO1) inhibition in cancer imm"}]}]}
>```
>%%
>*%%PREFIX%%22AbstractPurpose  Strategies fo%%HIGHLIGHT%% ==r Indolamine-2,3-dioxygenase 1== %%POSTFIX%%(IDO1) inhibition in cancer imm*
>%%LINK%%[[#^k2ag4jfduw|show annotation]]
>%%COMMENT%%
>吲哚胺2，3-双加氧酶（IDO）是一种胞内酶，催化L-色氨酸转化为N-甲酰基尼氨酸，是基尼氨酸途径中的第一步和速率控制步骤。 IDO是一种限速酶，催化色氨酸降解为酪氨酸，被认为对需要色氨酸增殖的T细胞具有耐受作用。IDO在功能性静止调节性T细胞的激活和调节中也起着重要作用。 IDO是一种含血红素的酶，催化吲哚环2,3双键的氧化裂解。IDO通过色氨酸饥饿抑制T细胞的活化，而T细胞的存活和增殖则受O2自由基和kynurenine衍生物的调节。IDO在自身免疫、感染和恶性肿瘤中起着至关重要的作用。 吲哚胺-2,3-双加氧酶（IDO）是一种重要的免疫调节酶，参与色氨酸的代谢，是Kynurenin途径的一部分。色氨酸在肿瘤组织中被肿瘤细胞或抗原提呈细胞表达的限速酶IDO分解。
>%%TAGS%%
>
^k2ag4jfduw


>%%
>```annotation-json
>{"created":"2022-08-29T12:07:15.336Z","updated":"2022-08-29T12:07:15.336Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":789,"end":987},{"type":"TextQuoteSelector","exact":"ls. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance","prefix":"lts, but failed in clinical tria","suffix":".Methods  In this study, we inve"}]}]}
>```
>%%
>*%%PREFIX%%lts, but failed in clinical tria%%HIGHLIGHT%% ==ls. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance== %%POSTFIX%%.Methods  In this study, we inve*
>%%LINK%%[[#^15lfdt9i4q4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^15lfdt9i4q4


>%%
>```annotation-json
>{"created":"2022-08-29T12:08:43.963Z","updated":"2022-08-29T12:08:43.963Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":4414,"end":5186},{"type":"TextQuoteSelector","exact":"Indoleamine-2,3-dioxygenase 1 (IDO1) is an enzyme catabolizing the first and rate-limiting step of the Kynure-nine (Kyn) pathway and is expressed in epithelial cells, macrophages and dendritic cells (Mbongue et al. 2015; Mellor  and  Munn,  2004;  Munn  et  al.  1999).  IDO1  is  involved in various processes exerting immunosuppres-sive effects [e.g. prevention of foetal rejection during preg-nancy (Mellor et al. 2001), suppression of autoimmune disease (Scott et al. 2009)].In the past, several IDO1 inhibitors were evaluated as possible new anticancer drugs (Yao et al. 2021). Initial tri-als showed promising therapeutic effects, but phase 3 trials were finally terminated, because they could not increase the efficacy of treatment, while showing more side effects ","prefix":"otherapy is of great importance.","suffix":"(Long et al. 2019).Recent eviden"}]}]}
>```
>%%
>*%%PREFIX%%otherapy is of great importance.%%HIGHLIGHT%% ==Indoleamine-2,3-dioxygenase 1 (IDO1) is an enzyme catabolizing the first and rate-limiting step of the Kynure-nine (Kyn) pathway and is expressed in epithelial cells, macrophages and dendritic cells (Mbongue et al. 2015; Mellor  and  Munn,  2004;  Munn  et  al.  1999).  IDO1  is  involved in various processes exerting immunosuppres-sive effects [e.g. prevention of foetal rejection during preg-nancy (Mellor et al. 2001), suppression of autoimmune disease (Scott et al. 2009)].In the past, several IDO1 inhibitors were evaluated as possible new anticancer drugs (Yao et al. 2021). Initial tri-als showed promising therapeutic effects, but phase 3 trials were finally terminated, because they could not increase the efficacy of treatment, while showing more side effects== %%POSTFIX%%(Long et al. 2019).Recent eviden*
>%%LINK%%[[#^2gtv65c69w9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2gtv65c69w9


>%%
>```annotation-json
>{"created":"2022-08-29T12:09:26.888Z","updated":"2022-08-29T12:09:26.888Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":5205,"end":6290},{"type":"TextQuoteSelector","exact":"Recent evidence indicates that the tumour microenvi-ronment (TME) mainly attributes to drug resistance (Ruf-fell and Coussens 2015). Especially the tumour associated macrophages (TAMs) attracted the interest of basic and clinical  scientists,  since  they  are  abundant  in  the  TME  and were suggested to play a crucial role in tumour pro-liferation, tumour maintenance, angiogenesis, and metas-tasis (Colegio et al. 2014; Pan et al. 2020; Valastyan and Weinberg, 2011). Thereby, understanding the immunosup-pressive local TME and the systemic immunological envi-ronment are critically important for translational cancer research.According to Mills, TAMs can be classified according to  their  activation  state  into  the  M1  phenotype  (antitu-mour, classically activated) and the M2 phenotype (pro-tumour,  alternatively  activated;  Mills  et  al.  2000).  The  subpopulations of macrophages coexist within tumours and the understanding of their relationship, their functions and their intra- and intertumoural differences are potential keys to improve current cancer therapies","prefix":"side effects (Long et al. 2019).","suffix":".Epithelial  cancer  cells  have"}]}]}
>```
>%%
>*%%PREFIX%%side effects (Long et al. 2019).%%HIGHLIGHT%% ==Recent evidence indicates that the tumour microenvi-ronment (TME) mainly attributes to drug resistance (Ruf-fell and Coussens 2015). Especially the tumour associated macrophages (TAMs) attracted the interest of basic and clinical  scientists,  since  they  are  abundant  in  the  TME  and were suggested to play a crucial role in tumour pro-liferation, tumour maintenance, angiogenesis, and metas-tasis (Colegio et al. 2014; Pan et al. 2020; Valastyan and Weinberg, 2011). Thereby, understanding the immunosup-pressive local TME and the systemic immunological envi-ronment are critically important for translational cancer research.According to Mills, TAMs can be classified according to  their  activation  state  into  the  M1  phenotype  (antitu-mour, classically activated) and the M2 phenotype (pro-tumour,  alternatively  activated;  Mills  et  al.  2000).  The  subpopulations of macrophages coexist within tumours and the understanding of their relationship, their functions and their intra- and intertumoural differences are potential keys to improve current cancer therapies== %%POSTFIX%%.Epithelial  cancer  cells  have*
>%%LINK%%[[#^ffc0mypfvl|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ffc0mypfvl


>%%
>```annotation-json
>{"created":"2022-08-29T12:12:30.670Z","updated":"2022-08-29T12:12:30.670Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":23810,"end":24106},{"type":"TextQuoteSelector","exact":"We  identified  higher  proportions  of    CD163+  and   CD68+163+ TAMs in tumour tissue than in healthy adjacent tissue (t test, p < 0.01).We identified a higher percentage of  IDO1+ cells among  CD68+ and  163+ TAMs in tumour tissue than in healthy adjacent tissue (t test, p < 0.01) (Fig. S4).","prefix":"adjacent tissues were performed.","suffix":"Changes in IDO1 expression after"}]}]}
>```
>%%
>*%%PREFIX%%adjacent tissues were performed.%%HIGHLIGHT%% ==We  identified  higher  proportions  of    CD163+  and   CD68+163+ TAMs in tumour tissue than in healthy adjacent tissue (t test, p < 0.01).We identified a higher percentage of  IDO1+ cells among  CD68+ and  163+ TAMs in tumour tissue than in healthy adjacent tissue (t test, p < 0.01) (Fig. S4).== %%POSTFIX%%Changes in IDO1 expression after*
>%%LINK%%[[#^jkrmrs8fuf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jkrmrs8fuf


>%%
>```annotation-json
>{"created":"2022-08-29T12:12:37.875Z","updated":"2022-08-29T12:12:37.875Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":24132,"end":24155},{"type":"TextQuoteSelector","exact":" after tumour resection","prefix":". S4).Changes in IDO1 expression","suffix":"Next,  we  evaluated  clinical  "}]}]}
>```
>%%
>*%%PREFIX%%. S4).Changes in IDO1 expression%%HIGHLIGHT%% ==after tumour resection== %%POSTFIX%%Next,  we  evaluated  clinical*
>%%LINK%%[[#^ocxghpbmi2b|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ocxghpbmi2b


>%%
>```annotation-json
>{"created":"2022-08-29T12:12:58.491Z","updated":"2022-08-29T12:12:58.491Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":24619,"end":24649},{"type":"TextQuoteSelector","exact":"as surrogate for IDO1 activity","prefix":"ls of Tryptophan and Kynurenine ","suffix":"The serum levels of Trp and Kyn "}]}]}
>```
>%%
>*%%PREFIX%%ls of Tryptophan and Kynurenine%%HIGHLIGHT%% ==as surrogate for IDO1 activity== %%POSTFIX%%The serum levels of Trp and Kyn*
>%%LINK%%[[#^c7k7t2xkf95|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^c7k7t2xkf95


>%%
>```annotation-json
>{"created":"2022-08-29T12:13:25.946Z","updated":"2022-08-29T12:13:25.946Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":27264,"end":27772},{"type":"TextQuoteSelector","exact":"Recent evidence indicates that macrophages in the TME contribute to immune dysregulation and therefore might play a critical role in resistance to IDO1 inhibitors. This study aims to gain insights into the significance of  IDO1+ immune cells in OSCC patients and to further study the link between IDO1 and macrophages, which may open new avenues for developing immune-based therapies focussing on the TME. To our knowledge, this is the first study regarding the role of   IDO1+ immune cells in OSCC patients.","prefix":"t (t test, p = 0.067).Discussion","suffix":"In the retrospective part of thi"}]}]}
>```
>%%
>*%%PREFIX%%t (t test, p = 0.067).Discussion%%HIGHLIGHT%% ==Recent evidence indicates that macrophages in the TME contribute to immune dysregulation and therefore might play a critical role in resistance to IDO1 inhibitors. This study aims to gain insights into the significance of  IDO1+ immune cells in OSCC patients and to further study the link between IDO1 and macrophages, which may open new avenues for developing immune-based therapies focussing on the TME. To our knowledge, this is the first study regarding the role of   IDO1+ immune cells in OSCC patients.== %%POSTFIX%%In the retrospective part of thi*
>%%LINK%%[[#^je18tql42k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^je18tql42k


>%%
>```annotation-json
>{"created":"2022-08-29T12:14:07.766Z","updated":"2022-08-29T12:14:07.766Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":30876,"end":31418},{"type":"TextQuoteSelector","exact":"To this point, a major obstacle remains the intricate heterogeneity of macrophages and evidence emerged that Mills paradigm of antitumour M1-like and pro-tumour M2-like macrophages has to be redefined. Results regarding the significance of TAMs in different cancers are contradictory, which might be attributed to the different cancer types but also to their functional polymorphism and distinct microenvironments. Therefore, TAM subpopulations with their specific markers and their distinct function urgently need to be further inves-tigated","prefix":" facilitating immune responses. ","suffix":" (Wu et al. 2020).Previously, ma"}]}]}
>```
>%%
>*%%PREFIX%%facilitating immune responses.%%HIGHLIGHT%% ==To this point, a major obstacle remains the intricate heterogeneity of macrophages and evidence emerged that Mills paradigm of antitumour M1-like and pro-tumour M2-like macrophages has to be redefined. Results regarding the significance of TAMs in different cancers are contradictory, which might be attributed to the different cancer types but also to their functional polymorphism and distinct microenvironments. Therefore, TAM subpopulations with their specific markers and their distinct function urgently need to be further inves-tigated== %%POSTFIX%%(Wu et al. 2020).Previously, ma*
>%%LINK%%[[#^a4vcuz440br|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^a4vcuz440br


>%%
>```annotation-json
>{"created":"2022-08-29T12:14:44.417Z","updated":"2022-08-29T12:14:44.417Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf","selector":[{"type":"TextPositionSelector","start":34718,"end":34871},{"type":"TextQuoteSelector","exact":"However, the temporal dynamics of IDO1 activation and therefore metabolite production in human immune cells after tumour resection are currently unknown.","prefix":"2004;  Taylor  and  Feng  1991).","suffix":"We observed an increase in IDO1 "}]}]}
>```
>%%
>*%%PREFIX%%2004;  Taylor  and  Feng  1991).%%HIGHLIGHT%% ==However, the temporal dynamics of IDO1 activation and therefore metabolite production in human immune cells after tumour resection are currently unknown.== %%POSTFIX%%We observed an increase in IDO1*
>%%LINK%%[[#^kco88d9oqw|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kco88d9oqw


>%%
>```annotation-json
>{"created":"2022-08-29T12:15:40.434Z","text":"bravo!","updated":"2022-08-29T12:15:40.434Z","document":{"title":"IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma","link":[{"href":"urn:x-pdf:7aa055955148d44798f1e7cdb186a4c4"},{"href":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}],"documentFingerprint":"7aa055955148d44798f1e7cdb186a4c4"},"uri":"vault:/hematology-theroy/papers/20220808/Struckmeier2022_Article_IDO1IsHighlyExpressedInMacroph.pdf"}
>```
>%%
>*%%PREFIX%%%%HIGHLIGHT%% ==== %%POSTFIX%%*
>%%LINK%%[[#^s0a4ds52cp|show annotation]]
>%%COMMENT%%
>bravo!
>%%TAGS%%
>
^s0a4ds52cp
